Rossari Biotech (ROSSARI) Q1 24/25 earnings summary

Executive summary

• Achieved record quarterly revenue, EBITDA, and PAT in Q1 FY25, with strong year-over-year growth in both revenue (19.3%) and profits (19.4%).

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2024, were approved by the Board and reviewed by the Audit Committee.

• Statutory auditors conducted a limited review and found no material misstatements in the results.

• Growth driven by robust volume increases in HPPC and TSC segments, while AHN remained stable.

• Continued expansion in international markets and customer base, with exports expected to be a key growth driver.

Financial highlights

• Consolidated revenue from operations for Q1 FY25 was ₹4,896.50 million, up from ₹4,106.06 million in Q1 FY24.

• Consolidated net profit after tax for Q1 FY25 was ₹348.99 million, compared to ₹292.19 million in Q1 FY24.

• EBITDA: ₹64.9 crore, up 12.5% year-over-year; EBITDA margin at 13.3% (down 80 bps YoY).

• EPS (diluted): ₹6.3, up from ₹5.3 in Q1 FY24.

• Total expenditure increased 18.2% year-over-year, with notable rise in other expenses (42.2%).

Outlook and guidance

• Management remains optimistic for the remainder of FY25, focusing on broadening the customer base, expanding geographies, and prioritizing higher-margin products.

• Exports and R&D-driven innovation expected to further strengthen global market position.

• The company continues to operate as a single segment focused on specialty chemicals, with ongoing expansion and new subsidiary incorporation.